Potential for targeted therapy in prostate cancers with ERG abnormalities.

about

Potential for targeted therapy in prostate cancers with ERG abnormalities.

Item

http://www.wikidata.org/entity/Q39501622

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Potential for targeted therapy in prostate cancers with ERG abnormalities.

@en

Potential for targeted therapy in prostate cancers with ERG abnormalities.

@nl

type

Item

label

Potential for targeted therapy in prostate cancers with ERG abnormalities.

@en

Potential for targeted therapy in prostate cancers with ERG abnormalities.

@nl

prefLabel

Potential for targeted therapy in prostate cancers with ERG abnormalities.

@en

Potential for targeted therapy in prostate cancers with ERG abnormalities.

@nl

P1476

Potential for targeted therapy in prostate cancers with ERG abnormalities.

@en

P2093

Liang Cheng

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin

Iniparib plus chemotherapy in metastatic triple-negative breast cancer.

Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma

Transcription factors as targets for cancer therapy.

P304

781-782

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/AJA.2011.100

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sean R. Williamson

P577

2011-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21785441

http://www.w3.org/2001/XMLSchema#string

P932

3739554

http://www.w3.org/2001/XMLSchema#string